One Biosciences, a precision oncology techbio company specialising in clinical-grade single-cell tumor transcriptomic profiling, has announced a €15 million Series A financing round.

Led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures, the funding will accelerate clinical development of the company’s proprietary OneMap platform and expand strategic partnerships in pharma and biotech.

The OneMap platform leverages artificial intelligence to create detailed functional profiles of patient tumors at the single-cell level. This approach aims to improve clinical decision-making, enhance patient selection, guide therapy development, and optimise clinical trial design. By analysing transcriptomic data from individual tumor cells, One Biosciences seeks to unlock insights that could personalise cancer treatment and accelerate drug development.

CEO Hedi Ben Brahim said the investment “enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development.” The funding brings One Biosciences’ total capital raised to over €20 million, including seed financing.

Co-founder Dr Céline Vallot, group leader at the Curie Institute, highlighted the platform’s AI algorithms trained on proprietary patient datasets, enhancing the ability to predict responses across various oncology therapies.

Dr Mehdi Touat from Assistance Publique – Hôpitaux de Paris (APHP) and Paris Brain Institute said that while next-generation sequencing has advanced cancer care, benefits have been limited to small patient groups. He emphasized that clinical-grade single-cell profiling holds promise to catalyse the next generation of diagnostic and therapeutic advances.

The financing will also support scaling collaborations with pharmaceutical and biotechnology partners, positioning One Biosciences to play a significant role in precision oncology’s evolving landscape.